<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">glaucoma</journal-id><journal-title-group><journal-title xml:lang="ru">Национальный журнал Глаукома</journal-title><trans-title-group xml:lang="en"><trans-title>National Journal glaucoma</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-4104</issn><issn pub-type="epub">2311-6862</issn><publisher><publisher-name>Federal State Budgetary Institution of Science “Krasnov Research Institute of Eye Diseases”</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25700/NJG.2019.04.08</article-id><article-id custom-type="elpub" pub-id-type="custom">glaucoma-266</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW OF LITERATURE</subject></subj-group></article-categories><title-group><article-title>Влияние местной гипотензивной терапии на состояние тканей глазной поверхности и исход антиглаукомных операций  у пациентов с первичной открытоугольной глаукомой</article-title><trans-title-group xml:lang="en"><trans-title>The effect of topical hypotensive therapy on ocular surface and glaucoma surgery outcomes in patients with primary open-angle glaucoma</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нагорнова</surname><given-names>З. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Nagornova</surname><given-names>Z. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант, ассистент кафедры</p><p>153012, Российская Федерация, Иваново, пр. Шереметевский, д. 8</p></bio><bio xml:lang="en"><p>M.D., assistant professor</p><p>8 Sheremetevskiy av., Ivanovo, Russian Federation, 153012</p></bio><email xlink:type="simple">myxazai@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куроедов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuroyedov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., начальник отделения, профессор кафедры офтальмологии</p><p>107014, Российская Федерация, Москва, ул. Б. Оленья, д. 8А</p></bio><bio xml:lang="en"><p>Med.Sc.D., Professor, Head of Ophthalmology Department</p><p>8A Bolshaya Olenya st., Moscow, Russian Federation, 107014</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петров</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrov</surname><given-names>S. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д.м.н., главный научный сотрудник отдела глаукомы</p><p>119021, Российская федерация, Москва, ул. Россолимо, 11А</p></bio><bio xml:lang="en"><p>Med.Sc.D., leading research associate</p><p>11 A,B Rossolimo St., Moscow, Russian Federation, 119021</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Селезнев</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Seleznev</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> доцент, к.м.н., доцент кафедры</p><p>153012, Российская Федерация, Иваново, пр. Шереметевский, д. 8</p></bio><bio xml:lang="en"><p>Ph.D., M.D., assistant professor</p><p>8 Sheremetevskiy av., Ivanovo, Russian Federation, 153012</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Газизова</surname><given-names>И. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Gazizova</surname><given-names>I. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д.м.н., заведующий отделением </p><p>197376, Российская Федерация, Санкт-Петербург,  ул. Академика Павлова, д. 12</p></bio><bio xml:lang="en"><p>Med.Sc.D., Head of Ophthalmology Department</p><p>12 Academy Pavlov St., Saint-Petersburg, Russian Federation, 197376</p><p> </p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павлова</surname><given-names>Л. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlova</surname><given-names>L. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p> врач-офтальмолог</p><p> </p></bio><xref ref-type="aff" rid="aff-5"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Ивановская государственная медицинская академия» Минздрава РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ivanovo State Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФКУ «ЦВКГ им. П.В. Мандрыка» МО РФ; Кафедра офтальмологии лечебного факультета им. акад. А.П. Нестерова ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Mandryka Military Clinical Hospital; Pirogov State National Medical University, Ophthalmology Department</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБНУ «НИИ глазных болезней»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Research Institute of Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><aff xml:lang="ru" id="aff-4"><institution>ФГНУ «Институт экспериментальной медицины» РАН</institution><country>Russian Federation</country></aff><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>«Доррат АльКади Медикал»</institution><country>Саудовская Аравия</country></aff><aff xml:lang="en"><institution>AlKadi Medical Group, Dorrat Al Kadi Polyclinic</institution><country>Saudi Arabia</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>17</day><month>12</month><year>2019</year></pub-date><volume>18</volume><issue>4</issue><fpage>96</fpage><lpage>107</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Нагорнова З.М., Куроедов А.В., Петров С.Ю., Селезнев А.В., Газизова И.Р., Павлова Л.С., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Нагорнова З.М., Куроедов А.В., Петров С.Ю., Селезнев А.В., Газизова И.Р., Павлова Л.С.</copyright-holder><copyright-holder xml:lang="en">Nagornova Z.M., Kuroyedov A.V., Petrov S.Y., Seleznev A.V., Gazizova I.R., Pavlova L.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.glaucomajournal.ru/jour/article/view/266">https://www.glaucomajournal.ru/jour/article/view/266</self-uri><abstract><p>На сегодняшний день глаукома является ведущей причиной необратимой слепоты. Единственным фактором, на который можно воздействовать и тем самым предотвратить потерю зрительных функций, является уровень внутриглазного давления (ВГД). Как правило, снижение офтальмотонуса начинают с местной медикаментозной терапии, которая, по некоторым данным, может неблагоприятно воздействовать на глазную поверхность и ухудшать прогноз возможной фистулизирующей хирургии. Причина этого заключается в том, что длительное применение различных гипотензивных капель, особенно с консервантом в составе, приводит к необратимым изменениям глазной поверхности, индуцирует хроническое воспаление, способствующее рубцеванию созданных путей оттока, что ограничивает и в конечном итоге блокирует отток водянистой влаги из передней камеры. При этом установлено, что бесконсервантная терапия продолжительностью менее 6 месяцев не оказывает негативного влияния на исход антиглаукомных операций (АГО). Поэтому, назначая местное гипотензивное лечение, следует помнить, что использование большого количества режимов с разнообразным сочетанием препаратов, пренебрежение к медикаментам без консерванта ухудшают прогноз будущей хирургии, зачастую неизбежной. Особенно важно это учитывать у пациентов с ожидаемо высокой продолжительностью жизни, у которых уже на старте рационально выбирать в качестве первого режима не содержащие консерванты капли и проводить АГО (минимально инвазивные хирургические вмешательства) как можно раньше.</p></abstract><trans-abstract xml:lang="en"><p>Today glaucoma is the leading cause of irreversible blindness. Intraocular pressure level is the only directly influenced factor which can stop visual function deterioration and prevent visual loss. Generally, IOP reduction starts with topical therapy, which can adversely affect the ocular surface and impair the prognosis of possible future surgery. Long-term medical therapy leads to irreversible changes of the ocular surface and induces chronic inflammation, which promotes scarring of the newly created outflow pathways. This in turn may hinder and ultimately block the outflow from the anterior chamber. It was found that the use of preservative free eyedrops for less than 6 months does not influence the outcomes of glaucoma filtration surgery. Therefore, when prescribing local hypotensive therapy, we should remember, that the use of large number of different drops worsen the prognosis of the possible future surgery. Preservative free eyedrops and early surgery should be preferred, especially in patients with a long life expectancy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>первичная открытоугольная глаукома</kwd><kwd>местная гипотензивная терапия</kwd><kwd>трабекулэктомия</kwd><kwd>бензалкония хлорид</kwd><kwd>аналоги простагландинов.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>primary open-angle glaucoma</kwd><kwd>local hypotensive therapy</kwd><kwd>trabeculectomy</kwd><kwd>benzalkonium chloride</kwd><kwd>prostaglandin analogues</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Berdeaux G., Lafuma A., Robert J., Salmon J. Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database. Clinical Ophtalmology. 2011; 5:361-367. doi: 10.2147/opth.s16888</mixed-citation><mixed-citation xml:lang="en">Berdeaux G., Lafuma A., Robert J., Salmon J. Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database. Clinical Ophtalmology. 2011; 5:361-367. doi: 10.2147/opth.s16888</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tham Y.C., Li X., Wong T.Y. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121(11):2081–2090. doi: 10.1016/j.ophtha</mixed-citation><mixed-citation xml:lang="en">Tham Y.C., Li X., Wong T.Y. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121(11):2081–2090. doi: 10.1016/j.ophtha</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Heijl A., Leske M.C., Bengtsson B. et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120:1268–79. doi: 10.1136/ bjo.2005.081224</mixed-citation><mixed-citation xml:lang="en">Heijl A., Leske M.C., Bengtsson B. et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120:1268–79. doi: 10.1136/ bjo.2005.081224</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Prum B.E., Rosenberg L.F., Gedde S.J. et al. Primary open-angle glaucoma preferred practice pattern (R) guidelines. Ophthalmology. 2016; 123(1):41–111. doi:10.1016/j.ophtha.2015.10.053</mixed-citation><mixed-citation xml:lang="en">Prum B.E., Rosenberg L.F., Gedde S.J. et al. Primary open-angle glaucoma preferred practice pattern (R) guidelines. Ophthalmology. 2016; 123(1):41–111. doi:10.1016/j.ophtha.2015.10.053</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gazizova I., Avdeev R., Aleksandrov A. et al. Multicenter study of intraocular pressure level in patients with moderate and advanced primary open-angle glaucoma on treatment. Invest Ophthalmol Vis Sci. 2016; 57(12):6470</mixed-citation><mixed-citation xml:lang="en">Gazizova I., Avdeev R., Aleksandrov A. et al. Multicenter study of intraocular pressure level in patients with moderate and advanced primary open-angle glaucoma on treatment. Invest Ophthalmol Vis Sci. 2016; 57(12):6470</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Abysheva L.D., Avdeev R.V., Alexandrov A.S., Bakunina N.A. et al. Safety characteristics of the established optimal values of the intraocular pressure upper limit in patients with advanced primary openangle glaucoma in terms of evidence-based medicine. RMJ. Clin Ophthalmol. 2015; 3:111–122. (In Russ.).</mixed-citation><mixed-citation xml:lang="en">Abysheva L.D., Avdeev R.V., Alexandrov A.S., Bakunina N.A. et al.  Safety characteristics of the established optimal values of the intraocular pressure upper limit in patients with advanced primary openangle glaucoma in terms of evidence-based medicine. RMJ. Clin Ophthalmol. 2015; 3:111–122. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tsai J.C. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009; 116:30–36. doi:10.1016/j. ophtha.2009.06.024</mixed-citation><mixed-citation xml:lang="en">Tsai J.C. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009; 116:30–36. doi:10.1016/j ophtha.2009.06.024</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Newman-Casey P.A., Robin A.L., Blachley T. et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015; 122(7):1308-1316. doi:10.1016/j.ophtha. 2015.03.026</mixed-citation><mixed-citation xml:lang="en">Newman-Casey P.A., Robin A.L., Blachley T. et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015; 122(7):1308-1316. doi:10.1016/j.ophtha. 2015.03.026</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Baudouin C., Labbe A., Liang H. et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retinal Eye Res. 2010; 29(4): 312-324. doi:10.1016/j.preteyeres.2010.03.001</mixed-citation><mixed-citation xml:lang="en">Baudouin C., Labbe A., Liang H. et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retinal Eye Res. 2010; 29(4): 312-324. doi:10.1016/j.preteyeres.2010.03.001</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Coleman A.L. Advances in glaucoma treatment and management: surgery. Invest Opthalmol Vis Sci. 2012; 53:2491. doi: 10.1136/bjo.2005.081224</mixed-citation><mixed-citation xml:lang="en">Coleman A.L. Advances in glaucoma treatment and management: surgery. Invest Opthalmol Vis Sci. 2012; 53:2491. doi: 10.1136/bjo.2005.081224</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ang G.S., Varga Z., Shaarawy T. Postoperative infection in penetrating versus non-penetrating glaucoma surgery. Br J Ophthalmol. 2010; 94(12):1571–1576. doi:10.1136/bjo.2009.163923</mixed-citation><mixed-citation xml:lang="en">Ang G.S., Varga Z., Shaarawy T. Postoperative infection in penetrating versus non-penetrating glaucoma surgery. Br J Ophthalmol. 2010; 94(12):1571–1576. doi:10.1136/bjo.2009.163923</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Cairns J.E. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol. 1968; 66(4):673–679. doi:10.1016/0002-9394(68) 91288-9</mixed-citation><mixed-citation xml:lang="en">Cairns J.E. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol. 1968; 66(4):673–679. doi:10.1016/0002-9394(68) 91288-9</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Sharifipour F., Yazdani S., Asadi M. et al. Modified deep sclerectomy for the surgical treatment of glaucoma. J Ophthalmic Vis Res. 2019; 14(2):144-150. doi:10.4103/jovr.jovr_228_17</mixed-citation><mixed-citation xml:lang="en">Sharifipour F., Yazdani S., Asadi M. et al. Modified deep sclerectomy for the surgical treatment of glaucoma. J Ophthalmic Vis Res. 2019; 14(2):144-150. doi:10.4103/jovr.jovr_228_17</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lama P.J., Fechtner R.D. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003; 48(3):314-346. doi:10.1016/s00396257(03)00038-9</mixed-citation><mixed-citation xml:lang="en">Lama P.J., Fechtner R.D. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003; 48(3):314-346. doi:10.1016/s00396257(03)00038-9</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Broadway C., Chang L.P. Trabeculectomy. Risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma. 2001; 10(3): 237–249. doi:10.1097/00061198-200106000-00017</mixed-citation><mixed-citation xml:lang="en">Broadway C., Chang L.P. Trabeculectomy. Risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma. 2001; 10(3): 237–249. doi:10.1097/00061198-200106000-00017</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Landers J., Martin K., Sarkies N. et al. A twenty-year follow-up study of trabeculectomy: risk factors and outcomes. Ophthalmology. 2012; 119(4): 694–702. doi:10.1016/j.ophtha.2011.09.043</mixed-citation><mixed-citation xml:lang="en">Landers J., Martin K., Sarkies N. et al. A twenty-year follow-up study of trabeculectomy: risk factors and outcomes. Ophthalmology. 2012; 119(4): 694–702. doi:10.1016/j.ophtha.2011.09.043</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">European Glaucoma Society: Terminology and Guidelines for Glaucoma. 3rd edition. Savona, Italy Editrice Dogma; 2008.</mixed-citation><mixed-citation xml:lang="en">European Glaucoma Society: Terminology and Guidelines for Glaucoma. 3rd edition. Savona, Italy Editrice Dogma; 2008.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Петров С.Ю., Ловпаче Дж.Н., Лоскутов И.А., Сафонова Д.М. Влияние местной гипотензивной терапии на состояние тканей переднего отрезка глаза и исход фистулизирующей хирургии глауком. Офтальмологические ведомости. 2017; 10(4):41-47. doi:10.17816/ OV10441-47</mixed-citation><mixed-citation xml:lang="en">Petrov S.Yu., Lovpache Dzh.N., Loskutov I.A., Safronova D.M. The influence of local IOP-lowering therapy on the anterior segment tissues and outcome of glaucoma filtering surgery. Ophthalmology J. 2017; 10(4):41-47. doi:10.17816/OV10441-47. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ellis J.S., Paull D.J., Dhingra S. et al. Growth factors and ocular scarring. Eur Ophthalmic Rev. 2009; 3(2):58–63.</mixed-citation><mixed-citation xml:lang="en">Ellis J.S., Paull D.J., Dhingra S. et al. Growth factors and ocular scarring. Eur Ophthalmic Rev. 2009; 3(2):58–63.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H.Y., Egbert P.R., Singh K. Long-term comparison of primary trabeculectomy with 5-fluorouracil vs mitomycin C in West Africa. J Glaucoma. 2008; 17:578–583. doi:10.1097/ijg.0b013e31816b304a</mixed-citation><mixed-citation xml:lang="en">Kim H.Y., Egbert P.R., Singh K. Long-term comparison of primary trabeculectomy with 5-fluorouracil vs mitomycin C in West Africa. J Glaucoma. 2008; 17:578–583. doi:10.1097/ijg.0b013e31816b304a</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Parul I., Aparna R. Ocular surface changes with long-term topical antiglaucoma medications. J Curr Glaucoma Practice. 2009; 3(3):1926. doi:10.5005/jp-journals-10008-1061</mixed-citation><mixed-citation xml:lang="en">Parul I., Aparna R. Ocular surface changes with long-term topical antiglaucoma medications. J Curr Glaucoma Practice. 2009; 3(3):1926.  doi:10.5005/jp-journals-10008-1061</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Fraunfelder F.W., Fraunfelder F.T., Chambers W.A. Drug-induced ocular side effects: clinical ocular toxicology E-Book. Elsevier Health Sciences. 2014; 221-225.</mixed-citation><mixed-citation xml:lang="en">Fraunfelder F.W., Fraunfelder F.T., Chambers W.A. Drug-induced ocular side effects: clinical ocular toxicology E-Book. Elsevier Health Sciences. 2014; 221-225.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Pieragostino D., Bucci S., Agnifili L. et al. Differential protein expression in tears of patients with primary open angle and pseudoexfoliative glaucoma. Mol BioSyst. 2012; 8(4):1017–1028. doi:10.1039/c1mb05357d</mixed-citation><mixed-citation xml:lang="en">Pieragostino D., Bucci S., Agnifili L. et al. Differential protein expression in tears of patients with primary open angle and pseudoexfoliative glaucoma. Mol BioSyst. 2012; 8(4):1017–1028. doi:10.1039/c1mb05357d</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Romero-Díaz de León L., Morales-León J.-E., Ledesma-Gil J., Navas A. Conjunctival and corneal sensitivity in patients under topical antiglaucoma treatment. International Ophthalmology. 2015; 36(3):299–303. doi:10.1007/s10792-015-0115-1</mixed-citation><mixed-citation xml:lang="en">Romero-Díaz de León L., Morales-León J.-E., Ledesma-Gil J., Navas A. Conjunctival and corneal sensitivity in patients under topical antiglaucoma treatment. International Ophthalmology. 2015; 36(3):299–303. doi:10.1007/s10792-015-0115-1</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Wu N., Chen Y., Yu X. et al. Changes in Corneal Biomechanical Properties after Long-Term Topical Prostaglandin Therapy. PLoS One. 2016; 17;11(5):e0155527. doi: 10.1371/journal.pone.0155527</mixed-citation><mixed-citation xml:lang="en">Wu N., Chen Y., Yu X. et al. Changes in Corneal Biomechanical Properties after Long-Term Topical Prostaglandin Therapy. PLoS One. 2016; 17;11(5):e0155527. doi: 10.1371/journal.pone.0155527</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Singh R., Joseph A., Umapathy T. et al. Impression cytology of the ocular surface. Brit J Ophthalmol. 2005; 89:1655-1659. doi:10.1136/ bjo.2005.073916</mixed-citation><mixed-citation xml:lang="en">Singh R., Joseph A., Umapathy T. et al. Impression cytology of the ocular surface. Brit J Ophthalmol. 2005; 89:1655-1659. doi:10.1136/ bjo.2005.073916</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Baratz K.H., Nau C.B., Winter E.J. et al. Effects of Glaucoma Medications on Corneal Endothelium, Keratocytes, and Subbasal Nerves Among Participants in the Ocular Hypertension Treatment Study. Clin Sci. 2006; 25(9):1046–1052. doi:10.1097/01.ico.0000230499.07273.c5</mixed-citation><mixed-citation xml:lang="en">Baratz K.H., Nau C.B., Winter E.J. et al. Effects of Glaucoma Medications on Corneal Endothelium, Keratocytes, and Subbasal Nerves Among Participants in the Ocular Hypertension Treatment Study. Clin Sci. 2006; 25(9):1046–1052. doi:10.1097/01.ico.0000230499.07273.c5</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Janson B.J., Alward W.L., Kwon Y.H. et al. Glaucoma-associated corneal endothelial cell damage: A review. Surv Ophthalmol. 2018; 63(4):500–506. doi:10.1016/j.survophthal.2017.11.002</mixed-citation><mixed-citation xml:lang="en">Janson B.J., Alward W.L., Kwon Y.H. et al. Glaucoma-associated corneal endothelial cell damage: A review. Surv Ophthalmol. 2018; 63(4):500–506. doi:10.1016/j.survophthal.2017.11.002</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu W., Kong X., Xu J., Sun X. Effects of Long-Term Antiglaucoma Eye Drops on Conjunctival Structures: An In Vivo Confocal Microscopy Study. J Ophthalmol. 2015:1–7. doi:10.1155/2015/165475 30. Mastropasqua L., Agnifili L., Fasanella V. et al. Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivoconfocal microscopy and impression cytology study. Acta Ophthalmologica. 2013; 91(5):397–405. doi:10.1111/aos.12131</mixed-citation><mixed-citation xml:lang="en">Zhu W., Kong X., Xu J., Sun X. Effects of Long-Term Antiglaucoma Eye Drops on Conjunctival Structures: An In Vivo Confocal Microscopy Study. J Ophthalmol. 2015:1–7. doi:10.1155/2015/165475 30. Mastropasqua L., Agnifili L., Fasanella V. et al. Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma:  an in vivoconfocal microscopy and impression cytology study. Acta Ophthalmologica. 2013; 91(5):397–405. doi:10.1111/aos.12131</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Mocan M.C., Uzunosmanoglu E., Kocabeyoglu S. et al. The association of chronic topical prostaglandin analog use with meibomian gland dysfunction. J Glaucoma. 2016; 25(9):770-774. doi: 10.1097/ IJG.0000000000000495</mixed-citation><mixed-citation xml:lang="en">Mocan M.C., Uzunosmanoglu E., Kocabeyoglu S. et al. The association of chronic topical prostaglandin analog use with meibomian gland dysfunction. J Glaucoma. 2016; 25(9):770-774. doi: 10.1097/ IJG.0000000000000495</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Lee T.H., Sung M.S., Heo H., Park S.W. Association between meibomian gland dysfunction and compliance of topical prostaglandin analogs in patients with normal tension glaucoma. PLoS One. 2018; 31;13(1):e0191398. doi:10.1371/journal.pone.0191398</mixed-citation><mixed-citation xml:lang="en">Lee T.H., Sung M.S., Heo H., Park S.W. Association between meibomian gland dysfunction and compliance of topical prostaglandin analogs in patients with normal tension glaucoma. PLoS One. 2018; 31;13(1):e0191398. doi:10.1371/journal.pone.0191398</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Jaenen N., Baudouin C., Pouliquen P. et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007; 17(3):341-349. doi:10.1177/112067210701700311</mixed-citation><mixed-citation xml:lang="en">Jaenen N., Baudouin C., Pouliquen P. et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007; 17(3):341-349. doi:10.1177/112067210701700311</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Pisella P.J., Pouliquen P., Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002; 86(4):418-423. doi:10.1136/bjo.86.4.418 35. Leung E.W., Medeiros F.A., Weinreb R.N. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008; 17(5):350-355. doi: 10.1097/IJG.0b013e31815c5f4f</mixed-citation><mixed-citation xml:lang="en">Pisella P.J., Pouliquen P., Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002; 86(4):418-423. doi:10.1136/bjo.86.4.418 35. Leung E.W., Medeiros F.A., Weinreb R.N. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008; 17(5):350-355. doi: 10.1097/IJG.0b013e31815c5f4f</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Uusitalo H., Chen E., Pfeiffer N. et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmologica. 2010; 88(3):329-336. doi: 10.1111/ j.1755-3768.2010.01907.x</mixed-citation><mixed-citation xml:lang="en">Uusitalo H., Chen E., Pfeiffer N. et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmologica. 2010; 88(3):329-336. doi: 10.1111/ j.1755-3768.2010.01907.x</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Chandrasekaran S., Cumming R.G., Rochtchina E., Mitchell P. Associations between elevated intraocular pressure and glaucoma, use of glaucoma medications, and 5–year incident cataract: the Blue Mountains Eye Study. Ophthalmology. 2009; 113(3):417–424. doi:10.1016/ j.ophtha.2005.10.050</mixed-citation><mixed-citation xml:lang="en">Chandrasekaran S., Cumming R.G., Rochtchina E., Mitchell P. Associations between elevated intraocular pressure and glaucoma, use of glaucoma medications, and 5–year incident cataract: the Blue Mountains Eye Study. Ophthalmology. 2009; 113(3):417–424. doi:10.1016/ j.ophtha.2005.10.050</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Schwab I.R., Linberg J.V., Gioia V.M. et al. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology. 1992; 99(2):197-202. doi: 10.1016/S0161-6420 (92)32001-9</mixed-citation><mixed-citation xml:lang="en">Schwab I.R., Linberg J.V., Gioia V.M. et al. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology. 1992; 99(2):197-202. doi: 10.1016/S0161-6420 (92)32001-9</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Thorne J.E., Anhalt G.J., Jabs D.A. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004; 111(1):45-52. doi: 10.1016/j.ophtha.2003.03.001</mixed-citation><mixed-citation xml:lang="en">Thorne J.E., Anhalt G.J., Jabs D.A. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004; 111(1):45-52. doi: 10.1016/j.ophtha.2003.03.001</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Lavin M.J., Wormald R.P., Migdal C.S., Hitchings R.A. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmology. 1990; 108(11):1543–1548. doi:10.1001/archopht.1990. 01070130045027</mixed-citation><mixed-citation xml:lang="en">Lavin M.J., Wormald R.P., Migdal C.S., Hitchings R.A. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmology. 1990; 108(11):1543–1548. doi:10.1001/archopht.1990. 01070130045027</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Краснов М.М., Зиангирова Г.Г., Шмырева В.Ф., Акберова С.И. Клинико-морфологические характеристики микроциркуляции конъюнктивы и радужки при открытоугольной глаукоме. Вестник офтальмологии. 1993; 109(5):7-10.</mixed-citation><mixed-citation xml:lang="en">Krasnov M.M., Ziangirova G.G., Shmyreva V.F., Akberova S.I. Clinical and morphological characteristics of conjunctival and iris microcirculation in open-angle glaucoma. Vestnik Oftalmologii. 1993; 109(5): 7-10. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Broadway D.C., Grierson I., O'Brien C., Hitchings R.A. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmology. 1994; 112(11):1437-1445. doi:10.1001/ archopht.1994.01090230051020</mixed-citation><mixed-citation xml:lang="en">Broadway D.C., Grierson I., O'Brien C., Hitchings R.A. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmology. 1994; 112(11):1437-1445. doi:10.1001/ archopht.1994.01090230051020</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Broadway D.C., Grierson I., Stürmer J. et al. Reversal of topical antiglaucoma medication effects on the conjunctiva. Ophthalmology. 1996; 114(3):262–267. doi:10.1001/archopht.1996.01100130258004 44. Broadway D.C., Grierson I., O’Brien C. et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmology. 1994; 112:1446–1454. doi:10.1001/archopht. 1994.01090230060021</mixed-citation><mixed-citation xml:lang="en">Broadway D.C., Grierson I., Stürmer J. et al. Reversal of topical antiglaucoma medication effects on the conjunctiva. Ophthalmology. 1996; 114(3):262–267. doi:10.1001/archopht.1996.01100130258004 44. Broadway D.C., Grierson I., O’Brien C. et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmology. 1994; 112:1446–1454. doi:10.1001/archopht. 1994.01090230060021</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Broadway D.C., Chang L.P. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma. 2001; 10(3):237-249. doi:10.1097/00061198-200106000-00017</mixed-citation><mixed-citation xml:lang="en">Broadway D.C., Chang L.P. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma. 2001; 10(3):237-249.  doi:10.1097/00061198-200106000-00017</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Breusegem C., Spielberg L., Van Ginderdeuren R. et al. Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology. 2010; 117:1324–1330. doi:10.1016/j.ophtha.2009.11.038</mixed-citation><mixed-citation xml:lang="en">Breusegem C., Spielberg L., Van Ginderdeuren R. et al. Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology. 2010; 117:1324–1330. doi:10.1016/j.ophtha.2009.11.038</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Detry-Morel M., Boschi A., Sempoux P. et al. Effect of local medications on intraocular pressure control following trabeculectomy. Bull Soc Belge Ophthalmology. 1995. 259:135–141.</mixed-citation><mixed-citation xml:lang="en">Detry-Morel M., Boschi A., Sempoux P. et al. Effect of local medications on intraocular pressure control following trabeculectomy. Bull Soc Belge Ophthalmology. 1995. 259:135–141.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Knape R.M., Hodapp E.A., Parrish R.K. Trabeculectomy outcomes. Ophthalmology. 2012; 119(12):2650-2651. doi: 10.1016/j.ophtha. 2012.07.071</mixed-citation><mixed-citation xml:lang="en">Knape R.M., Hodapp E.A., Parrish R.K. Trabeculectomy outcomes. Ophthalmology. 2012; 119(12):2650-2651. doi: 10.1016/j.ophtha. 2012.07.071</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Öztürker Z.K., Öztürker C., Bayraktar S. et al. Does the use of preoperative antiglaucoma medications influence trabeculectomy success? J Ocul Pharmacol Ther. 2014; 30:554–558. doi:10.1089/jop.2014</mixed-citation><mixed-citation xml:lang="en">Öztürker Z.K., Öztürker C., Bayraktar S. et al. Does the use of preoperative antiglaucoma medications influence trabeculectomy success? J Ocul Pharmacol Ther. 2014; 30:554–558. doi:10.1089/jop.2014</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Aritürk N., Oge I., Baris S. et al. The effects of antiglaucomatous agents on conjunctiva used for various durations. Int Ophthalmol. 1997; 20 (1–3):57–62. doi:10.1007/bf00212947</mixed-citation><mixed-citation xml:lang="en">Aritürk N., Oge I., Baris S. et al. The effects of antiglaucomatous agents on conjunctiva used for various durations. Int Ophthalmol. 1997; 20 (1–3):57–62. doi:10.1007/bf00212947</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Schwartz G.F. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol. 2005; 16 (2):114–121.</mixed-citation><mixed-citation xml:lang="en">Schwartz G.F. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol. 2005; 16 (2):114–121.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Dietlein T.S., Lüke C., Jacobi P.C., Krieglstein G.K. Individual factors influencing trabecular morphology in glaucoma patients undergoing filtration surgery. J Glaucoma. 2002; 11(3):197-202. doi:10.1097/ 00061198-200206000-00006</mixed-citation><mixed-citation xml:lang="en">Dietlein T.S., Lüke C., Jacobi P.C., Krieglstein G.K. Individual factors influencing trabecular morphology in glaucoma patients undergoing filtration surgery. J Glaucoma. 2002; 11(3):197-202. doi:10.1097/ 00061198-200206000-00006</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Sanders R., Sturrock S., Young J.D. Trabeculectomy in the second eye. Acta Ophthalmol Scand. 1996; 74(2):163-165. doi:10.1111/j.1600- 0420.1996.tb00063.x</mixed-citation><mixed-citation xml:lang="en">Sanders R., Sturrock S., Young J.D. Trabeculectomy in the second eye. Acta Ophthalmol Scand. 1996; 74(2):163-165. doi:10.1111/j.1600- 0420.1996.tb00063.x</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson D.H., Yoshikawa K., Brubaker R.F., Hodge D.O. The effect of long-term medical therapy on the outcome of filtration surgery. Am J Ophthalmol. 1998; 15;117(2):139-148. doi:10.1016/s00029394(14)73068-5</mixed-citation><mixed-citation xml:lang="en">Johnson D.H., Yoshikawa K., Brubaker R.F., Hodge D.O. The effect of long-term medical therapy on the outcome of filtration surgery. Am J Ophthalmol. 1998; 15;117(2):139-148. doi:10.1016/s00029394(14)73068-5</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Baudouin C. Ocular surface and external filtration surgery: mutual relationships. Dev Ophthalmol. 2017; 59:67-79. doi: 10.1159/ 000458487</mixed-citation><mixed-citation xml:lang="en">Baudouin C. Ocular surface and external filtration surgery: mutual relationships. Dev Ophthalmol. 2017; 59:67-79. doi: 10.1159/ 000458487</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Baudouin C., Garcher C., Haouat N. et al. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994; 101(3):454-460. doi:10.1016/s0161-6420(94)31322-4</mixed-citation><mixed-citation xml:lang="en">Baudouin C., Garcher C., Haouat N. et al. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994; 101(3):454-460. doi:10.1016/s0161-6420(94)31322-4</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Baudouin C., Nordmann J.P., Denis P.et al. Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefe’s Arch Clin Exper Ophthalmol. 2002; 240(11):929–935. doi:10.1007/ s00417-002-0581-9</mixed-citation><mixed-citation xml:lang="en">Baudouin C., Nordmann J.P., Denis P.et al. Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefe’s Arch Clin  Exper Ophthalmol. 2002; 240(11):929–935. doi:10.1007/ s00417-002-0581-9</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Hong S., Lee C.S., Seo K.Y. et al. Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am J Ophthalmol. 2006; 142(1):185-186. doi:10.1016/j.ajo.2006.02.056 59. Cvenkel B., Kopitar A.N., Ihan A. Inflammatory molecules in aqueous humour and on ocular surface and glaucoma surgery outcome. Mediators of Inflammation. 2010; 2010:1-7. doi:10.1155/2010/939602 60. Furtado J.M., Paula J.S., Soares E.G. et al. Perioperative conjunctival inflammation and trabeculectomy outcome. Ocul Immunol Inflamm. 2014; 22(3):183-188. doi:10.3109/09273948.2013.844263</mixed-citation><mixed-citation xml:lang="en">Hong S., Lee C.S., Seo K.Y. et al. Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am J Ophthalmol. 2006; 142(1):185-186. doi:10.1016/j.ajo.2006.02.056 59. Cvenkel B., Kopitar A.N., Ihan A. Inflammatory molecules in aqueous humour and on ocular surface and glaucoma surgery outcome. Mediators of Inflammation. 2010; 2010:1-7.  doi:10.1155/2010/939602 60. Furtado J.M., Paula J.S., Soares E.G. et al. Perioperative conjunctival inflammation and trabeculectomy outcome. Ocul Immunol Inflamm. 2014; 22(3):183-188. doi:10.3109/09273948.2013.844263</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Ihan A., Cvenkel B. Conjunctival epithelium expression of HLA-DR in glaucoma patients and its influence on the outcome of filtration surgery. Br J Ophthalmol. 2000; 84(6):648-650. doi:10.1136/ bjo.84.6.648</mixed-citation><mixed-citation xml:lang="en">Ihan A., Cvenkel B. Conjunctival epithelium expression of HLA-DR in glaucoma patients and its influence on the outcome of filtration surgery. Br J Ophthalmol. 2000; 84(6):648-650. doi:10.1136/ bjo.84.6.648</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Chong R.S., Jiang Y.Z., Boey P.Y. et al. Tear cytokine profile in medicated glaucoma patients: effect of monocyte chemoattractant protein 1 on early posttrabeculectomy outcome. Ophthalmology. 2010; 117:2353–2358. doi:10.1016/j.ophtha.2010.03.064</mixed-citation><mixed-citation xml:lang="en">Chong R.S., Jiang Y.Z., Boey P.Y. et al. Tear cytokine profile in medicated glaucoma patients: effect of monocyte chemoattractant protein 1 on early posttrabeculectomy outcome. Ophthalmology. 2010; 117:2353–2358. doi:10.1016/j.ophtha.2010.03.064</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Shields M.B., Scroggs M.W., Sloop C.M., Simmons R.B. Clinical and histopathologic observations concerning hypotony after trabeculectomy with adjunctive mitomycin C. Am J Ophthalmol. 1993; 116(6): 673-683. doi: 10.1016/S0002-9394(14)73465-8</mixed-citation><mixed-citation xml:lang="en">Shields M.B., Scroggs M.W., Sloop C.M., Simmons R.B. Clinical and histopathologic observations concerning hypotony after trabeculectomy with adjunctive mitomycin C. Am J Ophthalmol. 1993; 116(6): 673-683. doi: 10.1016/S0002-9394(14)73465-8</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Powers T.P., Stewart W.C., Stroman G.A. Ultrastructural features of filtration blebs with different clinical appearances. Ophthalmic Surg Lasers. 1996; 27(9):790-794.</mixed-citation><mixed-citation xml:lang="en">Powers T.P., Stewart W.C., Stroman G.A. Ultrastructural features of filtration blebs with different clinical appearances. Ophthalmic Surg Lasers. 1996; 27(9):790-794.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Picht G., Grehn F. Classification of filtering blebs in trabeculectomy: biomicroscopy and functionality. Curr Opin Ophthalmol. 1998; 9(2): 2-8. doi:10.1097/00055735-199804000-00002</mixed-citation><mixed-citation xml:lang="en">Picht G., Grehn F. Classification of filtering blebs in trabeculectomy: biomicroscopy and functionality. Curr Opin Ophthalmol. 1998; 9(2): 2-8. doi:10.1097/00055735-199804000-00002</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Sacu S., Rainer G., Findl O. et al. Correlation between the early morphological appearance of filtering blebs and outcome of trabeculectomy with mitomycin C. J Glaucoma. 2003; 12(5):430-435. doi:10.1097/00061198-200310000-00006</mixed-citation><mixed-citation xml:lang="en">Sacu S., Rainer G., Findl O. et al. Correlation between the early morphological appearance of filtering blebs and outcome of trabeculectomy with mitomycin C. J Glaucoma. 2003; 12(5):430-435. doi:10.1097/00061198-200310000-00006</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Vesti E. Filtering blebs: follow up of trabeculectomy. Ophthalmic Surgery. 1993; 24(4):249-255.</mixed-citation><mixed-citation xml:lang="en">Vesti E. Filtering blebs: follow up of trabeculectomy. Ophthalmic  Surgery. 1993; 24(4):249-255.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Amar N., Labbe A., Hamard P. et al. Filtering blebs and aqueous pathway: An immunocytological and in vivo confocal microscopy study. Ophthalmology. 2008; 115(7):1154-1161. doi: 10.1016/j. ophtha.2007.10.024</mixed-citation><mixed-citation xml:lang="en">Amar N., Labbe A., Hamard P. et al. Filtering blebs and aqueous pathway: An immunocytological and in vivo confocal microscopy study. Ophthalmology. 2008; 115(7):1154-1161. doi: 10.1016/j. ophtha.2007.10.024</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Stalmans I. Vascular endothelial growth factor (VEGF) and modulation of wound healing after glaucoma surgery. Verhandelingen - Koninklijke Academie voor Geneeskunde van België. 2010; 72(1-2): 41-53.</mixed-citation><mixed-citation xml:lang="en">Stalmans I. Vascular endothelial growth factor (VEGF) and modulation of wound healing after glaucoma surgery. Verhandelingen - Koninklijke Academie voor Geneeskunde van België. 2010; 72(1-2): 41-53.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Cvenkel B., Kopitar A.N., Ihan A. Correlation between filtering bleb morphology, expression of inflammatory marker HLA-DR by ocular surface, and outcome of trabeculectomy. J Glaucoma. 2013; 22(1):1520. doi: 10.1097/IJG.0b013e3182254051</mixed-citation><mixed-citation xml:lang="en">Cvenkel B., Kopitar A.N., Ihan A. Correlation between filtering bleb morphology,  expression of inflammatory marker HLA-DR by ocular surface, and outcome of trabeculectomy. J Glaucoma. 2013; 22(1):1520. doi: 10.1097/IJG.0b013e3182254051</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang X., Vadoothker S., Munir W.M., Saeedi O. Ocular surface disease and glaucoma medications: a clinical approach. Eye Contact Lens. 2019; 45(1):11-18. doi: 10.1097/ICL.0000000000000544</mixed-citation><mixed-citation xml:lang="en">Zhang X., Vadoothker S., Munir W.M., Saeedi O. Ocular surface disease and glaucoma medications: a clinical approach. Eye Contact Lens. 2019; 45(1):11-18. doi: 10.1097/ICL.0000000000000544</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Longstaff S., Wormald R.P., Mazover A., Hitchings R.A. Glaucoma triple procedures: efficacy of intraocular pressure control and visual outcome. Ophthalmic Surg. 1990; 21(11):786-793.</mixed-citation><mixed-citation xml:lang="en">Longstaff S., Wormald R.P., Mazover A., Hitchings R.A. Glaucoma triple procedures: efficacy of intraocular pressure control and visual outcome. Ophthalmic Surg. 1990; 21(11):786-793.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Klink T., Grehn F. Modern filtration surgery. Der Ophthalmologe. 2013; 110(4):299–305. doi:10.1007/s00347-012-2710-0</mixed-citation><mixed-citation xml:lang="en">Klink T., Grehn F. Modern filtration surgery. Der Ophthalmologe. 2013; 110(4):299–305. doi:10.1007/s00347-012-2710-0</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Leibowitz H.M., Bartlett J.D., Rich R. et al. Intraocular pressureraising potential of 1.0% rimexolone in patients responding to corticosteroids. Arch Ophthalmol. 1996; 114 (8):933–937. doi:10.1001/ archopht.1996.01100140141005</mixed-citation><mixed-citation xml:lang="en">Leibowitz H.M., Bartlett J.D., Rich R. et al. Intraocular pressureraising potential of 1.0% rimexolone in patients responding to corticosteroids. Arch Ophthalmol. 1996; 114 (8):933–937. doi:10.1001/ archopht.1996.01100140141005</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Fairbairn W.D., Thorson J.C. Fluorometholone. Anti-inflammatory and intraocular pressure effects. Arch Ophthalmol. 1971; 86(2): 138–141. doi:10.1001/archopht.1971.01000010140004</mixed-citation><mixed-citation xml:lang="en">Fairbairn W.D., Thorson J.C. Fluorometholone. Anti-inflammatory and intraocular pressure effects. Arch Ophthalmol. 1971; 86(2): 138–141. doi:10.1001/archopht.1971.01000010140004</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Baun O., Heegaard S., Kessing S.V., Prause J.U. The morphology of conjunctiva after long-term topical anti-glaucoma treatment. A quantitative analysis. Acta Ophthalmol Scand. 2009; 73(3):242–245. doi:/10.1111/ j.1600-0420.1995.tb00276.x</mixed-citation><mixed-citation xml:lang="en">Baun O., Heegaard S., Kessing S.V., Prause J.U. The morphology of conjunctiva after long-term topical anti-glaucoma treatment. A quantitative analysis. Acta Ophthalmol Scand. 2009; 73(3):242–245. doi:/10.1111/ j.1600-0420.1995.tb00276.x</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Francis B.A., Du L.T., Najafi K. et al. Histopathologic features of conjunctival filtering blebs. Arch Ophthalmol. 2005; 123 (2):166–170. doi:10.1001/archopht.123.2.166</mixed-citation><mixed-citation xml:lang="en">Francis B.A., Du L.T., Najafi K. et al. Histopathologic features of conjunctival filtering blebs. Arch Ophthalmol. 2005; 123 (2):166–170. doi:10.1001/archopht.123.2.166</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Nenciu A., Stefan C., Ardelean C. Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication. Oftalmologia. 2004; 48(1):35-42.</mixed-citation><mixed-citation xml:lang="en">Nenciu A., Stefan C., Ardelean C. Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication. Oftalmologia. 2004; 48(1):35-42.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Malesiński R., Bakunowicz-Łazarczyk A., Wysocka J. The role of chemokines CCL3/ MIP-1 alfa and CCL4/ MIP-1 beta in pathogenesis of dry eye syndrome. Klin Oczna. 2008; 110(7–9):277-279.</mixed-citation><mixed-citation xml:lang="en">Malesiński R., Bakunowicz-Łazarczyk A., Wysocka J. The role of chemokines CCL3/ MIP-1 alfa and CCL4/ MIP-1 beta in pathogenesis of dry eye syndrome. Klin Oczna. 2008; 110(7–9):277-279.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Lark K.K., Pasha A.S., Yan X., Edward D.P. The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts. J Glaucoma. 1999; 8(1):72–76. doi:10.1097/00061198-199902000-000</mixed-citation><mixed-citation xml:lang="en">Lark K.K., Pasha A.S., Yan X., Edward D.P. The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts. J Glaucoma. 1999; 8(1):72–76. doi:10.1097/00061198-199902000-000</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Liang H., Baudouin C., Labbe A. et al. Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study. PLoS One. 2012; 7(3):e.33913. doi:10.1371/journal.pone.0033913</mixed-citation><mixed-citation xml:lang="en">Liang H., Baudouin C., Labbe A. et al. Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study. PLoS One. 2012; 7(3):e.33913. doi:10.1371/journal.pone.0033913</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Kim E.J., Kim Y.H., Kang S.H., Lee K.W., Park Y.J. In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells. Korean J Ophthalmol. 2013; 27(6):446–453. doi:10.3341/kjo.2013.27.6.446</mixed-citation><mixed-citation xml:lang="en">Kim E.J., Kim Y.H., Kang S.H., Lee K.W., Park Y.J. In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells. Korean J Ophthalmol. 2013; 27(6):446–453. doi:10.3341/kjo.2013.27.6.446</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Brasnu E., Brignole-Baudouin F., Riancho L. et al. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008; 33(4):303-312. doi:10.1080/02713680801971857</mixed-citation><mixed-citation xml:lang="en">Brasnu E., Brignole-Baudouin F., Riancho L. et al. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008; 33(4):303-312. doi:10.1080/02713680801971857</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Boimer C., Birt C.M. Preservative exposure and surgical outcomes in glaucoma patients: The PESO study. J Glaucoma. 2013; 22(9): 730–745. doi:10.1097/ijg.0b013e31825af67</mixed-citation><mixed-citation xml:lang="en">Boimer C., Birt C.M. Preservative exposure and surgical outcomes  in glaucoma patients: The PESO study. J Glaucoma. 2013; 22(9): 730–745. doi:10.1097/ijg.0b013e31825af67</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Lorenz K., Wasielica-Poslednik J., Bell K. et al. Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma. PLoS ONE. 2017; 12(2): e0171636. doi:10.1371/journal.pone.0171636</mixed-citation><mixed-citation xml:lang="en">Lorenz K., Wasielica-Poslednik J., Bell K. et al. Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma. PLoS ONE. 2017; 12(2): e0171636. doi:10.1371/journal.pone.0171636</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Еричев В.П., Амбарцумян К.Г., Федоров А.А. Клинико-морфологические доказательства влияния консервантов на поверхность глаза при первичной открытоугольной глаукоме. Национальный журнал глаукома. 2014; 4:13-22.</mixed-citation><mixed-citation xml:lang="en">Erichev V.P., Ambartsumyan K.H., Fedorov A.A. Clinical and morphological evidence of the effect of preservatives on the eye surface in primary open-angle glaucoma. National J Glaucoma. 2014; 13(4):13-22. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Steven D.W., Alaghband P., Lim K.S. Preservatives in glaucoma medication. Brit J Ophthalmol. 2018; 102:1497-1503. doi:10.1136/bjophthalmol-2017-311544</mixed-citation><mixed-citation xml:lang="en">Steven D.W., Alaghband P., Lim K.S. Preservatives in glaucoma medication. Brit J Ophthalmol. 2018; 102:1497-1503. doi:10.1136/bjophthalmol-2017-311544</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Berry M., Pult H., Purslow C., Murphy P.J. Mucins and ocular signs in symptomatic and asymptomatic contact lens wear. Optom Vis Sci. 2008; 85(10):930–938. doi:10.1097/opx.0b013e318188896b</mixed-citation><mixed-citation xml:lang="en">Berry M., Pult H., Purslow C., Murphy P.J. Mucins and ocular signs in symptomatic and asymptomatic contact lens wear. Optom Vis Sci. 2008; 85(10):930–938. doi:10.1097/opx.0b013e318188896b</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y., Liu Y., Xu D., Li J. Latanoprost-induced cytokine and chemokine release from human tenon's capsule fibroblasts: role of MAPK and NF-κB signaling pathways. J Glaucoma. 2015;24(9):635-641. doi: 10.1097/IJG.0000000000000140</mixed-citation><mixed-citation xml:lang="en">Liu Y., Liu Y., Xu D., Li J. Latanoprost-induced cytokine and chemokine release from human tenon's capsule fibroblasts: role of MAPK and NF-κB signaling pathways. J Glaucoma. 2015;24(9):635-641. doi: 10.1097/IJG.0000000000000140</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Trzeciecka A., Paterno J.J., Toropainen E. et al. Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa. Eur J Pharmacol. 2016; 788:12–20. doi:10.1016/j.ejphar.2016</mixed-citation><mixed-citation xml:lang="en">Trzeciecka A., Paterno J.J., Toropainen E. et al. Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa. Eur J Pharmacol. 2016; 788:12–20. doi:10.1016/j.ejphar.2016</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Kucukevcilioglu M., Bayer A., Uysal Y. et al. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin Exp Ophthalmol. 2014; 42:126–31. doi:10.1111/ceo.12163</mixed-citation><mixed-citation xml:lang="en">Kucukevcilioglu M., Bayer A., Uysal Y. et al. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin Exp Ophthalmol. 2014; 42:126–31. doi:10.1111/ceo.12163</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Miki T., Naito T., Fujiwara M. et al. Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy. PLoS One. 2017; 12:e0181550. doi:10.1371/journal.pone.0181550</mixed-citation><mixed-citation xml:lang="en">Miki T., Naito T., Fujiwara M. et al. Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy. PLoS One. 2017; 12:e0181550. doi:10.1371/journal.pone.0181550</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Абышева Л.Д., Александров А.С., Арапиев М.У. и др. Оптимизация лечебно-диагностического процесса у пациентов с первичной открытоугольной глаукомой. Национальный журнал глаукома. 2016; 15(2):19–35.</mixed-citation><mixed-citation xml:lang="en">Abysheva L.D., Alexandrov A.S., Arapiev M.U. et al. Optimization of diagnosis and treatment options in primary open-angle glau- coma patients. National J Glaucoma. 2016; 15(2):19–35. (In Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
